|
1
|
Fahrmann JF, Katayama H, Irajizad E, Chakraborty A, Kato T, Mao X, Park S, Murage E, Rusling L, Yu CY, Cai Y, Hsiao FC, Dennison JB, Tran H, Ostrin E, Wilson DO, Yuan JM, Vykoukal J, Hanash S. Plasma Based Protein Signatures Associated with Small Cell Lung Cancer. Cancers (Basel) 2021; 13:cancers13163972. [PMID: 34439128 PMCID: PMC8391533 DOI: 10.3390/cancers13163972] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 08/03/2021] [Accepted: 08/04/2021] [Indexed: 02/04/2023] Open
Abstract
Small-cell-lung cancer (SCLC) is associated with overexpression of oncogenes including Myc family genes and YAP1 and inactivation of tumor suppressor genes. We performed in-depth proteomic profiling of plasmas collected from 15 individuals with newly diagnosed early stage SCLC and from 15 individuals before the diagnosis of SCLC and compared findings with plasma proteomic profiles of 30 matched controls to determine the occurrence of signatures that reflect disease pathogenesis. A total of 272 proteins were elevated (area under the receiver operating characteristic curve (AUC) ≥ 0.60) among newly diagnosed cases compared to matched controls of which 31 proteins were also elevated (AUC ≥ 0.60) in case plasmas collected within one year prior to diagnosis. Ingenuity Pathway analyses of SCLC-associated proteins revealed enrichment of signatures of oncogenic MYC and YAP1. Intersection of proteins elevated in case plasmas with proteomic profiles of conditioned medium from 17 SCLC cell lines yielded 52 overlapping proteins characterized by YAP1-associated signatures of cytoskeletal re-arrangement and epithelial-to-mesenchymal transition. Among samples collected more than one year prior to diagnosis there was a predominance of inflammatory markers. Our integrated analyses identified novel circulating protein features in early stage SCLC associated with oncogenic drivers.
Collapse
Affiliation(s)
- Johannes F. Fahrmann
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Hiroyuki Katayama
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Ehsan Irajizad
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Ashish Chakraborty
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Taketo Kato
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Xiangying Mao
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Soyoung Park
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Eunice Murage
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Leona Rusling
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Chuan-Yih Yu
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Yinging Cai
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Fu Chung Hsiao
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Jennifer B. Dennison
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Hai Tran
- Department of Thoracic-Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA;
| | - Edwin Ostrin
- Department of Pulmonary Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA;
| | - David O. Wilson
- Division of Pulmonary, Allergy and Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA;
| | - Jian-Min Yuan
- Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA;
- Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
| | - Jody Vykoukal
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
| | - Samir Hanash
- Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA; (J.F.F.); (H.K.); (E.I.); (A.C.); (T.K.); (X.M.); (S.P.); (E.M.); (L.R.); (C.-Y.Y.); (Y.C.); (F.C.H.); (J.B.D.); (J.V.)
- Correspondence:
| |
Collapse
|
|
2
|
Rüb AM, Tsakmaklis A, Gräfe SK, Simon MC, Vehreschild MJ, Wuethrich I. Biomarkers of human gut microbiota diversity and dysbiosis. Biomark Med 2021; 15:137-148. [PMID: 33442994 DOI: 10.2217/bmm-2020-0353] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 11/04/2020] [Indexed: 12/24/2022] Open
Abstract
The association of gut microbiota dysbiosis with various human diseases is being substantiated with increasing evidence. Metabolites derived from both, microbiota and the human host play a central role in disease susceptibility and disease progression by extensively modulating host physiology and metabolism. Several of these metabolites have the potential to serve as diagnostic biomarkers for monitoring disease states in conjunction with intestinal microbiota dysbiosis. In this narrative review we evaluate the potential of trimethylamine-N-oxide, short-chain fatty acids, 3-indoxyl sulfate, p-cresyl sulfate, secondary bile acids, hippurate, human β-defensin-2, chromogranin A, secreted immunoglobulins and zonulin to serve as biomarkers for metabolite profiling and diagnostic suitability for dysbiosis and disease.
Collapse
Affiliation(s)
- Alina M Rüb
- Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
| | - Anastasia Tsakmaklis
- Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
| | - Stefanie K Gräfe
- Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany
| | - Marie-Christine Simon
- Department of Nutrition & Food Sciences, Nutrition & Microbiota, University of Bonn, Bonn, Germany
| | - Maria Jgt Vehreschild
- Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Irene Wuethrich
- Department of Biosystems Science & Engineering, ETH Zurich, Basel, Switzerland
| |
Collapse
|